21st Austria weekly - Valneva; AT&S (20/06/2022)

21st Austria weekly - Valneva; AT&S 20/06/2022 [pic1]Valneva: Austrian/French vaccine company Valneva and Pfizer announced that they have entered into an Equity Subscription Agreement updated the terms of their Collaboration License for Lyme disease candidate VLA15. As previously on April 26 2022 plans to initiate Phase 3 study VLA15 in third quarter 2022. part Agreement

Related Keywords

Austria ,China ,Ukraine ,Austrian , ,Pfizer ,Equity Subscription Agreement ,License Agreement ,Euronext Paris ,Equity Subscription ,Austria Weekly ,Partner Asset Management Gmbh ,Herausforderungen Des Marktes ,Besuchen Sie ,Ic1 Valneva ,Austrian French ,Valneva ,Equity ,Subscription ,Agreement ,Collaboration ,License ,Flyme ,Vla15 ,Gas ,April ,Phase ,